You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Nursing Perspectives: How to Manage Your Patients With NSCLC on Immunotherapy

  • Authors: Mark M. Awad, MD, PhD; Beth Eaby-Sandy, MSN, CRNP; Marianne Davies, DNP, ACNP, AOCNP, FAAN
  • CE Released: 6/25/2021
  • Valid for credit through: 6/25/2022
Start Activity

Target Audience and Goal Statement

This activity is intended for oncology nurses/nurse practitioners (NPs).

The goal of this activity is to improve oncology nurses'/NPs' awareness and understanding regarding the clinical evidence supporting the use of immune checkpoint inhibitors (ICIs), either with or without chemotherapy, as treatment for non-small cell lung cancer (NSCLC) and strategies to manage these patients in clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial evidence evaluating the use of ICIs in the treatment of NSCLC
    • Use of biomarkers to guide immunotherapy selection for patients with NSCLC
  • Have greater competence related to
    • Managing patients who receive immunotherapy as part of their treatment plan for NSCLC
    • Educating patients on potential immune-related adverse events (irAEs) 


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.



  • Mark M. Awad, MD, PhD

    Clinical Director​
    Lowe Center for Thoracic Oncology​
    Dana-Farber Cancer Institute​
    Assistant Professor of Medicine​
    Harvard Medical School​
    Boston, Massachusetts​


    Disclosure: Mark M. Awad, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: ArcherDX; Ariad; AstraZeneca; Blueprint Medicine; Bristol Myers Squibb; EMD Serono; Genentech; Gritstone; Maverick; Merck; Mirati; Nektar; NextCure; Norvartis; Panvaxal/NovaRx; Syndax
    Grants for clinical research from: AstraZeneca; Bristol Myers Squibb; Genentech, Lilly

  • Beth Eaby-Sandy, MSN, CRNP

    Nurse Practitioner ​
    Abramson Cancer Center ​
    University of Pennsylvania ​
    Philadelphia, Pennsylvania ​


    Disclosure: Beth Eaby-Sandy, MSN, CRNP, has the following relevant financial relationships:
    Speaker or a member of a speakers bureau for: AstraZeneca; Jazz; Merck; Takeda

  • Marianne Davies, DNP, ACNP, AOCNP, FAAN

    Nurse Practitioner​
    Lecturer in Nursing ​
    Yale University School of Nursing​
    New Haven, Connecticut


    Disclosure: Marianne Davies, DNP, ACNP, AOCNP, FAAN, has no relevant financial relationships.


  • Davecia R. Cameron, MS

    Medical Education Director, Medscape, LLC


    Medical Education Director, Medscape, LLC

CE Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Nursing Perspectives: How to Manage Your Patients With NSCLC on Immunotherapy

Authors: Mark M. Awad, MD, PhD; Beth Eaby-Sandy, MSN, CRNP; Marianne Davies, DNP, ACNP, AOCNP, FAANFaculty and Disclosures

CE Released: 6/25/2021

Valid for credit through: 6/25/2022


Select Any Chapter to Begin

Did you know that immunotherapy helped more than 15% of patients with advanced NSCLC live for at least 5 years longer?

  • Print